Traders should view this as a major de-risking event for Eli Lilly's migraine franchise. The ruling eliminates near-term patent invalidity risk for Emgality, supports pricing power, and enhances the value of Lilly's neurology pipeline. Consider increasing exposure ahead of potential competitive responses from Teva or appeals.
Price Chart
Executive Summary
The U.S. Court of Appeals for the Federal Circuit reversed a lower court's judgment and ruled in favor of Eli Lilly, reinstating a jury verdict that Teva's patents covering methods of using humanized anti-CGRP antibodies to treat headaches are valid and infringed by Lilly's Emgality. The ruling overturns a prior invalidation of the patents on written description and enablement grounds, significantly strengthening Eli Lilly's legal position.
Court Ruling Details
Key Facts
- Federal Circuit reversed the district court's judgment of invalidity and reinstated the jury verdict in favor of Teva (plaintiff) against Eli Lilly (defendant)
- The appellate court held that Teva's '045, '907, and '908 patents satisfy both written description and enablement requirements under 35 U.S.C. § 112
- The ruling supports the validity of patents covering the use of humanized anti-CGRP antagonist antibodies for treating headache, including Eli Lilly's Emgality
- The court rejected Eli Lilly's argument that the patents lacked adequate written description due to disclosing only one humanized antibody (G1) while claiming a broad genus
- The decision affirms that prior knowledge of murine anti-CGRP antibodies and routine humanization techniques support sufficient disclosure for the claimed genus
Financial Impact
Removes existential legal threat to Emgality, which generated $2.8B in 2025 sales. Avoids potential damages and future royalty obligations. Strengthens Eli Lilly's IP position in migraine market.
Risk Factors
- Teva may seek rehearing en banc or petition the Supreme Court
- Ongoing litigation or new challenges could emerge on other grounds
- Competitors may accelerate development of alternative CGRP inhibitors
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-2pxskqsa-LLY |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 5w ago | Press Release | $1,115.70 $1,179.27 | ▲ +5.70% | ▲ +3.83% | $1,257.03 (+12.67%) |
Sep 8, 2026 5w ago | Court Ruling | $1,123.91 $1,157.49 | ▲ +2.99% | ▲ +1.02% | $1,257.03 (+11.84%) |
Aug 18, 2026 8w ago | Insider Cluster | $1,225.73 $1,137.82 | ▼ −7.17% | ▼ −5.86% | $1,257.03 (+2.55%) |
Aug 11, 2026 9w ago | Insider Cluster | $1,215.02 $1,124.21 | ▼ −7.47% | ▼ −6.42% | $1,257.03 (+3.46%) |
Aug 7, 2026 10w ago | Court Ruling | $1,185.71 $1,149.36 | ▼ −3.07% | ▼ −2.67% | $1,257.03 (+6.01%) |
Aug 5, 2026 10w ago | 8-K | $1,169.86 $1,160.08 | ▼ −0.84% | ▼ −0.23% | $1,257.03 (+7.45%) |
Aug 4, 2026 10w ago | Court Ruling | $1,115.68 $1,160.00 | ▲ +3.97% | ▲ +5.21% | $1,257.03 (+12.67%) |
Jul 31, 2026 11w ago | Court Ruling | $1,148.84 $1,174.61 | ▼ −2.24% | ▲ +0.74% | $1,257.03 (−9.42%) |
Jul 30, 2026 11w ago | Court Ruling | $1,154.97 $1,176.10 | ▲ +1.83% | ▼ −2.14% | $1,257.03 (+8.84%) |
Jul 22, 2026 12w ago | Press Release | $1,163.01 $1,280.34 | ▲ +10.09% | ▲ +7.19% | $1,257.03 (+8.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access